Pharmaceutical Market Europe - July/August 2017

In the July-August issue of PME, we report from a recent debate on 100 healthy years. As life expectancy increases, it focused on how stakeholders can ensure the last decades of life are healthy ones.

The event in Darmstadt, Germany saw experts from the likes of UNAIDS and the World Obesity Federation tackle managing chronic diseases, communicating health messages and achieving behaviour change.

We also look at two areas of European regulatory change. Firstly in clinical trials, where industry preparations are - or should be - underway for new ways to assess the ethics of a study, and then in the medical device space where moves are being made to reduce patient exposure to safety risks.

Recently we’ve seen Biogen explore quantum computing to speed up its drug discovery efforts in neurology and GlaxoSmithKline apply artificial intelligence from Exscientia to its own research. Alongside coverage of these developments, we assess this month the potential of AI across the pharma life cycle, from regulatory submissions to transforming clinical trials and patient safety.

Elsewhere in this issue of PME we look at how pharma marketing does not take place within a vacuum and how promotional instruments can be wielded more effectively.